Ads
related to: second line treatment for hcc tumor- Unresectable HCC Therapy
Combination Treatment For
Unresectable HCC. Visit Site.
- View The Dosing Regimen
See The Dosing Schedule For A
Unresectable HCC Treatment
- Clinical Study Data
View Data For An Unresectable
Hepatocellular Carcinoma Treatment.
- Official Oncologist Site
Visit Official HCP Site To Learn
About An Immunotherapy Option.
- Safety Info From A Study
See Adverse Reaction Data For A
First-Line Unresectable HCC Therapy
- Connect With A Rep
Have Questions? Find Your Local
Representative To Get Answers.
- Unresectable HCC Therapy
Search results
Results From The WOW.Com Content Network
Treatment of hepatocellular carcinoma varies by the stage of disease, a person's likelihood to tolerate surgery, and availability of liver transplantation: Curative intention: for limited disease, when the cancer is limited to one or more areas of within the liver, surgically removing the malignant cells may be curative.
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.
Ramucirumab([5]), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. [3] [4] Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist.
Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, [9] [11] but discontinued for use in triple-negative breast cancer (TNBC). [12]
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. [ 9 ] [ 10 ] It is a small-molecule tyrosine-kinase inhibitor (TKI) of c-Met (HGFR) and VEGFR2 , and also inhibits AXL , RET , and FLT3 .
Ads
related to: second line treatment for hcc tumor